Bcl-2 mediates chemoresistance in matched pairs of primary Eμ-myc lymphomas in vivo

Blood Cells, Molecules, and Diseases

Volumn 27, Issue 1, 2001, Pages 206-216

  Schmitt, Clemens A ^a   Lowe, Scott W ^a  

^a Watson School of Biological Sciences   (United States)

Author keywords

Apoptosis; bcl 2; Chemoresistance; E myc mouse; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENHANCER REGION; GENE ISOLATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSFER; HISTOPATHOLOGY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; TRANSGENE;

DROMAIUS NOVAEHOLLANDIAE;

EID: 0035049735     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.2000.0372     Document Type: Article

References (31)

1. Apoptosis and the dilemma of cancer chemotherapy
2. Apoptosis and therapy
3. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression
4. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
5. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
6. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline
7. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
8. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
9. p53 status and the efficacy of cancer therapy in vivo
10. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
11. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease
12. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
13. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma
14. Prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
15. Cellular expression of antiapoptotic Bcl-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A Children's Cancer Group study
16. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer
17. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors
18. The tumor microenvironment as a determinant of cancer cell survival: A possible mechanism for de novo drug resistance
19. Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells
20. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival
21. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells
22. Differential effects of Bcl-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation
23. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells
24. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
25. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
26. The Eμ-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells
27. DNA damage responses and chemosensitivity in the Eμ-myc mouse lymphoma model
28. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
29. Derivatives of Moloney murine sarcoma virus capable of being transcribed in embryonal carcinoma stem cells have gained a functional SP1 binding site
30. Genetic analysis of chemoresistance in primary murine lymphomas
31. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts